Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China
· Delayed Price · Currency is CNY 1.730
+0.020 (1.17%)
Apr 29, 2026, 3:00 PM CST
Kangmei Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 12.43 | 8.57 | 102.52 | -2,688 | 7,918 | Upgrade
|
| Depreciation & Amortization | 311.09 | 334.57 | 346.18 | 365.69 | 603.22 | Upgrade
|
| Other Amortization | 21.05 | 38.83 | 22.49 | 27.73 | 35.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.85 | -39.47 | -19.61 | -0.98 | -64.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 185.84 | 31.47 | 99.97 | 307.46 | 2,643 | Upgrade
|
| Loss (Gain) From Sale of Investments | -90.6 | -59.18 | -44.4 | -0.75 | -188.79 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 24.89 | -238.47 | 213.41 | 1,192 | Upgrade
|
| Other Operating Activities | -7.7 | 114.76 | 196.51 | 278.14 | 2,577 | Upgrade
|
| Change in Accounts Receivable | -128.26 | -502.64 | 215.15 | -339.53 | -746.88 | Upgrade
|
| Change in Inventory | 96.05 | -34.32 | -93.01 | -253.62 | 1,666 | Upgrade
|
| Change in Accounts Payable | -290.34 | -347.41 | -896.42 | 1,321 | -15,587 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | - | 0.59 | Upgrade
|
| Operating Cash Flow | 111.35 | -427.63 | -317.52 | -749.96 | 214.21 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | -79.23% | Upgrade
|
| Capital Expenditures | -217.06 | -61.71 | -99.74 | -48.12 | -171.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 39.79 | 164.33 | 52.25 | 1.55 | 77.9 | Upgrade
|
| Divestitures | - | 27.3 | 9.85 | - | 57.72 | Upgrade
|
| Investment in Securities | - | - | - | - | -0.53 | Upgrade
|
| Other Investing Activities | - | 10 | - | 0.55 | 0.04 | Upgrade
|
| Investing Cash Flow | -177.27 | 139.92 | -37.64 | -46.02 | -36.51 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 127.64 | Upgrade
|
| Long-Term Debt Issued | - | 0.1 | - | - | - | Upgrade
|
| Total Debt Issued | - | 0.1 | - | - | 127.64 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -97.03 | Upgrade
|
| Long-Term Debt Repaid | -43.5 | -54.46 | -72.71 | -94.95 | -48.66 | Upgrade
|
| Total Debt Repaid | -43.5 | -54.46 | -72.71 | -94.95 | -145.69 | Upgrade
|
| Net Debt Issued (Repaid) | -43.5 | -54.36 | -72.71 | -94.95 | -18.05 | Upgrade
|
| Issuance of Common Stock | - | 1.15 | - | - | 1,800 | Upgrade
|
| Common Dividends Paid | - | -0.75 | - | -0.9 | -13.82 | Upgrade
|
| Dividends Paid | - | -0.75 | - | -0.9 | -13.82 | Upgrade
|
| Other Financing Activities | 332.75 | 228.78 | -48.14 | -21.01 | 0.25 | Upgrade
|
| Financing Cash Flow | 289.25 | 174.81 | -120.85 | -116.86 | 1,768 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.01 | -0 | 0 | 0 | -0.04 | Upgrade
|
| Net Cash Flow | 223.31 | -112.91 | -476.01 | -912.84 | 1,946 | Upgrade
|
| Free Cash Flow | -105.71 | -489.34 | -417.27 | -798.08 | 42.58 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -94.16% | Upgrade
|
| Free Cash Flow Margin | -2.01% | -9.43% | -8.56% | -19.09% | 1.03% | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.03 | -0.04 | -0.06 | 0.00 | Upgrade
|
| Cash Interest Paid | - | - | - | 1.06 | - | Upgrade
|
| Cash Income Tax Paid | 155.54 | 295.28 | 211.36 | 284.45 | 235.31 | Upgrade
|
| Levered Free Cash Flow | -2.17 | -313.1 | 1,126 | 117.24 | -6,029 | Upgrade
|
| Unlevered Free Cash Flow | -2.17 | -299.73 | 1,161 | 166.55 | -5,391 | Upgrade
|
| Change in Working Capital | -319.91 | -882.08 | -782.71 | 747.5 | -14,501 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.